194 related articles for article (PubMed ID: 30206765)
1. Concomitant PPARα and FXR Activation as a Putative Mechanism of NASH Improvement after Gastric Bypass Surgery: a GEO Datasets Analysis.
Mazzini GS; Khoraki J; Dozmorov M; Browning MG; Wijesinghe D; Wolfe L; Gurski RR; Campos GM
J Gastrointest Surg; 2019 Jan; 23(1):51-57. PubMed ID: 30206765
[TBL] [Abstract][Full Text] [Related]
2. Gastric Bypass Increases Circulating Bile Acids and Activates Hepatic Farnesoid X Receptor (FXR) but Requires Intact Peroxisome Proliferator Activator Receptor Alpha (PPARα) Signaling to Significantly Reduce Liver Fat Content.
Mazzini GS; Khoraki J; Browning MG; Wu J; Zhou H; Price ET; Wolfe LG; Mangino MJ; Campos GM
J Gastrointest Surg; 2021 Apr; 25(4):871-879. PubMed ID: 33555523
[TBL] [Abstract][Full Text] [Related]
3. Roux-en-Y Gastric Bypass Improves Metabolic Conditions in Association with Increased Serum Bile Acids Level and Hepatic Farnesoid X Receptor Expression in a T2DM Rat Model.
Yan Y; Sha Y; Huang X; Yuan W; Wu F; Hong J; Fang S; Huang B; Hu C; Wang B; Zhang X
Obes Surg; 2019 Sep; 29(9):2912-2922. PubMed ID: 31079286
[TBL] [Abstract][Full Text] [Related]
4. Integrated Analysis of Key Genes and Pathways Involved in Nonalcoholic Steatohepatitis Improvement After Roux-en-Y Gastric Bypass Surgery.
Chen F; Zhou Y; Wu Z; Li Y; Zhou W; Wang Y
Front Endocrinol (Lausanne); 2020; 11():611213. PubMed ID: 33603714
[TBL] [Abstract][Full Text] [Related]
5. Farnesoid X receptor contributes to body weight-independent improvements in glycemic control after Roux-en-Y gastric bypass surgery in diet-induced obese mice.
Li K; Zou J; Li S; Guo J; Shi W; Wang B; Han X; Zhang H; Zhang P; Miao Z; Li Y
Mol Metab; 2020 Jul; 37():100980. PubMed ID: 32305491
[TBL] [Abstract][Full Text] [Related]
6. Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease.
Cherla DV; Rodriguez NA; Vangoitsenhoven R; Singh T; Mehta N; McCullough AJ; Brethauer SA; Schauer PR; Aminian A
Surg Endosc; 2020 May; 34(5):2266-2272. PubMed ID: 31359195
[TBL] [Abstract][Full Text] [Related]
7. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.
Francque S; Verrijken A; Caron S; Prawitt J; Paumelle R; Derudas B; Lefebvre P; Taskinen MR; Van Hul W; Mertens I; Hubens G; Van Marck E; Michielsen P; Van Gaal L; Staels B
J Hepatol; 2015 Jul; 63(1):164-73. PubMed ID: 25703085
[TBL] [Abstract][Full Text] [Related]
8. Liver Function in Patients With Nonalcoholic Fatty Liver Disease Randomized to Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy: A Secondary Analysis of a Randomized Clinical Trial.
Kalinowski P; Paluszkiewicz R; Ziarkiewicz-Wróblewska B; Wróblewski T; Remiszewski P; Grodzicki M; Krawczyk M
Ann Surg; 2017 Nov; 266(5):738-745. PubMed ID: 28767558
[TBL] [Abstract][Full Text] [Related]
9. Effects of Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease in an Obese Rat Model.
Watanabe K; Ohta M; Takayama H; Tada K; Shitomi Y; Kawasaki T; Kawano Y; Endo Y; Iwashita Y; Inomata M
Obes Surg; 2018 Jun; 28(6):1532-1539. PubMed ID: 29280057
[TBL] [Abstract][Full Text] [Related]
10. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study.
Froylich D; Corcelles R; Daigle C; Boules M; Brethauer S; Schauer P
Surg Obes Relat Dis; 2016 Jan; 12(1):127-31. PubMed ID: 26077701
[TBL] [Abstract][Full Text] [Related]
11. A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR).
Zhou S; You H; Qiu S; Yu D; Bai Y; He J; Cao H; Che Q; Guo J; Su Z
Biomed Pharmacother; 2022 Oct; 154():113577. PubMed ID: 35988420
[TBL] [Abstract][Full Text] [Related]
12. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease.
Aguilar-Olivos NE; Carrillo-Córdova D; Oria-Hernández J; Sánchez-Valle V; Ponciano-Rodríguez G; Ramírez-Jaramillo M; Chablé-Montero F; Chávez-Tapia NC; Uribe M; Méndez-Sánchez N
Ann Hepatol; 2015; 14(4):487-93. PubMed ID: 26019035
[TBL] [Abstract][Full Text] [Related]
13. Changes in Bile Acid Metabolism, Transport, and Signaling as Central Drivers for Metabolic Improvements After Bariatric Surgery.
Browning MG; Pessoa BM; Khoraki J; Campos GM
Curr Obes Rep; 2019 Jun; 8(2):175-184. PubMed ID: 30847736
[TBL] [Abstract][Full Text] [Related]
14. Roux-en-Y gastric bypass induces hepatic transcriptomic signatures and plasma metabolite changes indicative of improved cholesterol homeostasis.
Lalloyer F; Mogilenko DA; Verrijken A; Haas JT; Lamazière A; Kouach M; Descat A; Caron S; Vallez E; Derudas B; Gheeraert C; Baugé E; Despres G; Dirinck E; Tailleux A; Dombrowicz D; Van Gaal L; Eeckhoute J; Lefebvre P; Goossens JF; Francque S; Staels B
J Hepatol; 2023 Oct; 79(4):898-909. PubMed ID: 37230231
[TBL] [Abstract][Full Text] [Related]
15. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21.
Cyphert HA; Ge X; Kohan AB; Salati LM; Zhang Y; Hillgartner FB
J Biol Chem; 2012 Jul; 287(30):25123-38. PubMed ID: 22661717
[TBL] [Abstract][Full Text] [Related]
16. Impact of Nonalcoholic Steatohepatitis on the Outcome of Patients Undergoing Roux-en-Y Gastric Bypass Surgery: a Propensity Score-Matched Analysis.
Abbassi Z; Orci L; Meyer J; Sgardello SD; Goossens N; Rubbia-Brandt L; Spahr L; Buchs NC; Mönig SP; Toso C; Hagen ME; Jung MK
Obes Surg; 2022 Jan; 32(1):74-81. PubMed ID: 34546514
[TBL] [Abstract][Full Text] [Related]
17.
Qin D; Liu S; Lu Y; Yan Y; Zhang J; Cao S; Chen M; Chen N; Huang W; Wang L; Chen X; Zhang L
Theranostics; 2022; 12(14):6130-6142. PubMed ID: 36168631
[No Abstract] [Full Text] [Related]
18. Increased Bile Acid Signals After Duodenal-Jejunal Bypass Improve Non-alcoholic Steatohepatitis (NASH) in a Rodent Model of Diet-Induced NASH.
Tsuchiya T; Naitoh T; Nagao M; Tanaka N; Watanabe K; Imoto H; Miyachi T; Motoi F; Unno M
Obes Surg; 2018 Jun; 28(6):1643-1652. PubMed ID: 29235014
[TBL] [Abstract][Full Text] [Related]
19. Treatment of NASH with Gastric Bypass.
Jirapinyo P; Thompson CC
Curr Gastroenterol Rep; 2018 Sep; 20(10):49. PubMed ID: 30244334
[TBL] [Abstract][Full Text] [Related]
20. Reduced peroxisome proliferator-activated receptor-α and bile acid nuclear receptor NR1H4/FXR may affect the hepatic immune microenvironment of biliary atresia.
Ma Y; Lu L; Tan K; Li Z; Guo T; Wu Y; Wu W; Zheng L; Fan F; Mo J; Gong Z
Front Immunol; 2022; 13():875593. PubMed ID: 36090996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
